An Open-Label Study to Evaluate Efficacy and Safety of Long-Term Treatment With ACH-0144471 in Participants Who Completed Clinical Study ACH471-100
Latest Information Update: 03 Nov 2023
Price :
$35 *
At a glance
- Drugs Danicopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Sponsors Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease
- 30 Sep 2022 Status changed from active, no longer recruiting to completed.
- 27 Jun 2022 Planned End Date changed from 24 Mar 2022 to 9 Aug 2022.
- 18 Feb 2022 Planned End Date changed from 16 Aug 2021 to 24 Mar 2022.